a stronger push to offer drug therapy for primary prevention of breast cancer in higher-risk women

You'll see a stronger push to offer drug therapy for primary prevention of breast cancer in higher-risk women.

Tamoxifen and raloxifene are approved for prevention in women with a 5-year risk of breast cancer ≥ 1.66%...about the risk of an average woman over 60.

But age alone usually isn't enough to start drug therapy. Benefits generally don't outweigh risks unless the woman also has a family history of breast cancer, atypical hyperplasia, or other risks.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote